

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

(Bond Stock Code: 05818)

**COMPLETION OF CONCURRENT REPURCHASE OF US\$180,000,000
6.25 PER CENT. CONVERTIBLE BONDS DUE 2028**

**Sole Global Coordinator, Sole Overall Coordinator,
Sole Bookrunner and Sole Dealer Manager**



Reference is made to the announcements of Luye Pharma Group Ltd. (the “**Company**”) dated 3 June 2026, 4 June 2026 and 11 June 2026 in relation to the Concurrent Repurchase and issue of the Bonds (the “**Announcements**”). Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise stated.

COMPLETION OF THE CONCURRENT REPURCHASE OF US\$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028 BY THE COMPANY

The Board is pleased to announce that all the conditions precedent to the Concurrent Repurchase as set out in the Dealer Manager Agreement have been satisfied and that the Concurrent Repurchase has been completed on 11 June 2026. An aggregate principal amount of US\$89.74 million of the Existing Convertible Bonds has been repurchased (the “**Repurchased Bonds**”) which represents approximately 49.9 per cent. of the initial principal amount of the Existing Convertible Bonds. The Company has procured Citibank N.A. to arrange for the cancellation of the Repurchased Bonds.

Following the completion of the Concurrent Repurchase and as at the date of this announcement, the remaining outstanding aggregate principal amount of the Existing Convertible Bonds is approximately US\$90.26 million.

WAIVER FROM COMPLIANCE WITH THE CODE ON SHARE BUY-BACKS (THE “BUY-BACKS CODE”)

The Company has applied to the Executive (as defined in the Codes on Takeovers and Mergers and Share Buy-backs) for a waiver from compliance with the relevant provisions of the Buy-backs Code in respect of the Concurrent Repurchase and the Executive has granted such waiver having considered all relevant circumstances.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 11 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.